{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:09:09Z","timestamp":1790179749937,"version":"4.1.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003009","name":"Science and Technology Development Fund","doi-asserted-by":"publisher","award":["43254"],"award-info":[{"award-number":["43254"]}],"id":[{"id":"10.13039\/501100003009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007637","name":"German University in Cairo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007637","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite the fact that chemoimmunotherapy has emerged as a key component in the era of cancer immunotherapy, it is challenged by the complex tumor microenvironment (TME) that is jam-packed with cellular and non-cellular immunosuppressive components. The aim of this study was to design a nanoparticulate system capable of sufficiently accumulating in the tumor and spleen to mediate local and systemic immune responses, respectively. The study also aimed to remodel the immunosuppressive TME. For such reasons, multi-functional polylactic-co-glycolic acid (PLGA) nanoparticles (NPs) were engineered to simultaneously eradicate the cancer cells, silence the tumor-associated fibroblasts (TAFs), and re-educate the tumor-associated macrophages (TAMs) using doxorubicin, losartan, and metformin, respectively. These agents were also selected for their ability to tip the balance of the splenic immune cells towards immunostimulatory phenotypes. To establish TAM and TAF cultures, normal macrophages and fibroblasts were incubated with B16F10 melanoma cell (Mel)-derived secretome. Drug-loaded PLGA NPs were prepared, characterized, and tested in the target cell types. Organ distribution of fluorescein-loaded PLGA NPs was evaluated in a mouse model of melanoma. Finally, the local and systemic effects of different combination therapy programs were portrayed. The in vitro studies showed that the drug-loaded PLGA NPs could significantly ablate the immunosuppressive nature of Mel and skew TAMs and TAFs towards more favorable phenotypes. While in vivo, PLGA NPs were proven to exhibit long blood circulation time and to localize preferentially in the tumor and the spleen. The combination of either metformin or losartan with doxorubicin was superior to the monotherapy, both locally and systemically. However, the three-agent combo produced detrimental effects in the form of compromised well-being, immune depletion, and metastasis. These findings indicate the potential of TME remodeling as means to prime the tumors for successful chemoimmunotherapy. In addition, they shed light on the importance of the careful use of combination therapies and the necessity of employing dose-reduction strategies.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>D-NPs doxorubicin-loaded NPs, M-NPs metformin-loaded NPs, L-NPs losartan-loaded NPs, TAMs tumor-associated macrophages, TAFs tumor-associated fibroblasts, PD-L1 programmed death ligand 1, TNF-\u03b1 tumor necrosis factor alpha, TGF-\u03b2 transforming growth factor beta, CD206\/40\/86 cluster of differentiation 206\/40\/86, \u03b1-SMA alpha-smooth muscle actin, MMPs matrix metalloproteases<\/jats:p>","DOI":"10.1007\/s13346-023-01413-9","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T15:02:08Z","timestamp":1692802928000},"page":"491-509","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Multitarget, multiagent PLGA nanoparticles for simultaneous tumor eradication and TME remodeling in a melanoma mouse model"],"prefix":"10.1007","volume":"14","author":[{"given":"Asmaa","family":"Ramzy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya H.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally I.","family":"Hassanein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9281-9184","authenticated-orcid":false,"given":"Aya A.","family":"Sebak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,23]]},"reference":[{"key":"1413_CR1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.pdpdt.2018.05.017","volume":"23","author":"AA Sebak","year":"2018","unstructured":"Sebak AA, Gomaa II, ElMeshad AN, AbdelKader MH. Targeted photodynamic-induced singlet oxygen production by peptide-conjugated biodegradable nanoparticles for treatment of skin melanoma. Photodiagnosis Photodyn Ther. 2018;23:181\u20139.","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"1413_CR2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.pdpdt.2017.01.186","volume":"18","author":"I Gomaa","year":"2017","unstructured":"Gomaa I, Sebak A, Afifi N, Abdel-Kader M. Liposomal delivery of ferrous chlorophyllin: a novel third generation photosensitizer for in vitro PDT of melanoma. Photodiagnosis Photodyn Ther. 2017;18:162\u201370.","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"1413_CR3","doi-asserted-by":"crossref","first-page":"12452","DOI":"10.18632\/oncotarget.23746","volume":"9","author":"R Marconcini","year":"2018","unstructured":"Marconcini R, et al. Current status and perspectives in immunotherapy for metastatic melanoma. Oncotarget. 2018;9:12452\u201370.","journal-title":"Oncotarget"},{"key":"1413_CR4","first-page":"1","volume":"6","author":"L Bezu","year":"2015","unstructured":"Bezu L, et al. Combinatorial strategies for the induction of immunogenic cell death. Front Immunol. 2015;6:1\u201311.","journal-title":"Front Immunol"},{"key":"1413_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0376-0","volume":"6","author":"MU Mushtaq","year":"2018","unstructured":"Mushtaq MU, et al. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers. J Immunother Cancer. 2018;6:1\u201314.","journal-title":"J Immunother Cancer"},{"key":"1413_CR6","first-page":"1444","volume":"22","author":"A Sebak","year":"2021","unstructured":"Sebak A, El-Shenawy B, El-Safy S, El-Shazly M. From passive targeting to personalized nanomedicine: multidimentional insights on nanoparticles\u2019 interaction with the tumor microenvironment. Curr Pharm Des. 2021;22:1444\u201365.","journal-title":"Curr Pharm Des"},{"key":"1413_CR7","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1242\/jcs.116392","volume":"125","author":"FR Balkwill","year":"2012","unstructured":"Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012;125:5591\u20136.","journal-title":"J Cell Sci"},{"key":"1413_CR8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","volume":"21","author":"D Hanahan","year":"2012","unstructured":"Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21:309\u201322.","journal-title":"Cancer Cell"},{"key":"1413_CR9","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1158\/0008-5472.CAN-17-2320","volume":"78","author":"P Dauer","year":"2018","unstructured":"Dauer P, et al. Inactivation of cancer-associated-fibroblasts disrupts oncogenic signaling in pancreatic cancer cells and promotes its regression. Cancer Res. 2018;78:1321\u201333.","journal-title":"Cancer Res"},{"key":"1413_CR10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.phrs.2017.05.004","volume":"126","author":"S Yang","year":"2017","unstructured":"Yang S, Gao H. Nanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy. Pharmacol Res. 2017;126:97\u2013108.","journal-title":"Pharmacol Res"},{"key":"1413_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2018.05.002","author":"B Theek","year":"2018","unstructured":"Theek B, et al. Histidine-rich glycoprotein-induced vascular normalization improves EPR-mediated drug targeting to and into tumors. J Control Release. 2018. https:\/\/doi.org\/10.1016\/j.jconrel.2018.05.002.","journal-title":"J Control Release"},{"key":"1413_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-021-02402-z","volume":"22","author":"NNV Radharani","year":"2022","unstructured":"Radharani NNV, et al. Tumor-associated macrophage derived IL-6 enriches cancer stem cell population and promotes breast tumor progression via Stat-3 pathway. Cancer Cell Int. 2022;22:1\u201319.","journal-title":"Cancer Cell Int"},{"key":"1413_CR13","doi-asserted-by":"crossref","unstructured":"Norouzi M, et al. Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles. Sci Rep. 2020;10:1\u201318.","DOI":"10.1038\/s41598-020-68017-y"},{"key":"1413_CR14","doi-asserted-by":"crossref","first-page":"6485","DOI":"10.7150\/thno.34429","volume":"9","author":"CG Da Silva","year":"2019","unstructured":"Da Silva CG, et al. Effective chemoimmunotherapy by co-delivery of doxorubicin and immune adjuvants in biodegradable nanoparticles. Theranostics. 2019;9:6485.","journal-title":"Theranostics"},{"key":"1413_CR15","doi-asserted-by":"crossref","first-page":"8845","DOI":"10.2147\/IJN.S273713","volume":"2020","author":"A Sebak","year":"2020","unstructured":"Sebak A, et al. Distinct proteins in protein corona of nanoparticles represent a promising venue for endogenous targeting part I: in vitro release and uptake perspective. Int J Nanomedicine. 2020;2020:8845\u201362.","journal-title":"Int J Nanomedicine"},{"key":"1413_CR16","doi-asserted-by":"crossref","first-page":"9539","DOI":"10.2147\/IJN.S273721","volume":"2020","author":"A Sebak","year":"2020","unstructured":"Sebak A, et al. Distinct proteins in protein corona of nanoparticles represent a promising venue for endogenous targeting part II: in vitro and in vivo kinetics study. Int J Nanomedicine. 2020;2020:9539\u201356.","journal-title":"Int J Nanomedicine"},{"key":"1413_CR17","doi-asserted-by":"crossref","first-page":"S1434","DOI":"10.1016\/j.annonc.2021.10.151","volume":"32","author":"A Sebak","year":"2021","unstructured":"Sebak A, Hindy A, Hassanein SI, Gad MZ. 132P Tumor-responsive nanoparticles exhibit selective immunomodulatory effects: a Trojan horse strategy. Ann Oncol. 2021;32:S1434.","journal-title":"Ann Oncol"},{"key":"1413_CR18","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3389\/fphar.2017.00952","volume":"8","author":"B Zhang","year":"2017","unstructured":"Zhang B, Hu Y, Pang Z. Modulating the tumor microenvironment to enhance tumor nanomedicine delivery. Front Pharmacol. 2017;8:952.","journal-title":"Front Pharmacol"},{"key":"1413_CR19","doi-asserted-by":"crossref","unstructured":"Kurelac I, Umesh Ganesh N, Iorio M, Porcelli AM, Gasparre G. The multifaceted effects of metformin on tumor microenvironment. Semin Cell Dev Biol.\u00a02020;98:90\u201397. (2020).","DOI":"10.1016\/j.semcdb.2019.05.010"},{"key":"1413_CR20","doi-asserted-by":"crossref","unstructured":"Carlos-Escalante JA, et al. The use of antihypertensive drugs as coadjuvant therapy in cancer. Front Oncol.\u00a02021;11.","DOI":"10.3389\/fonc.2021.660943"},{"key":"1413_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-022-09200-4","volume":"22","author":"SW Keith","year":"2022","unstructured":"Keith SW, et al. Angiotensin blockade therapy and survival in pancreatic cancer: a population study. BMC Cancer. 2022;22:1\u20139.","journal-title":"BMC Cancer"},{"key":"1413_CR22","doi-asserted-by":"crossref","unstructured":"Wei J,\u00a0et al. Retrospective clinical study of renin-angiotensin system blockers in lung cancer patients with hypertension. PeerJ. 2019.","DOI":"10.7717\/peerj.8188"},{"key":"1413_CR23","doi-asserted-by":"crossref","unstructured":"Li Q, et al. Synergy of Losartan and chemotherapy for patients with cholangiocarcinoma: a propensity score-matched analysis. Front Oncol. 2022;12:989080.","DOI":"10.3389\/fonc.2022.989080"},{"key":"1413_CR24","doi-asserted-by":"crossref","first-page":"1075823","DOI":"10.3389\/fonc.2023.1075823","volume":"13","author":"RC Augustin","year":"2023","unstructured":"Augustin RC, et al. Metformin is associated with improved clinical outcomes in patients with melanoma: a retrospective, multi-institutional study. Front Oncol. 2023;13:1075823.","journal-title":"Front Oncol"},{"key":"1413_CR25","doi-asserted-by":"crossref","unstructured":"Afzal MZ, Mercado RR, Shirai K. Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1\/anti-CTLA-4) in metastatic malignant melanoma. J Immunother Cancer.\u00a02018;6.","DOI":"10.1186\/s40425-018-0375-1"},{"key":"1413_CR26","doi-asserted-by":"crossref","unstructured":"Arnold SA,\u00a0et al. Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGF\u03b2 activation. PLoS One.\u00a02012;7.","DOI":"10.1371\/journal.pone.0031384"},{"key":"1413_CR27","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1158\/0008-5472.CAN-13-1545","volume":"74","author":"D Alizadeh","year":"2014","unstructured":"Alizadeh D, et al. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res. 2014;74:104\u201318.","journal-title":"Cancer Res"},{"key":"1413_CR28","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002773","volume":"9","author":"R Veeramachaneni","year":"2021","unstructured":"Veeramachaneni R, et al. Metformin generates profound alterations in systemic and tumor immunity with associated antitumor effects. J Immunother Cancer. 2021;9: e002773.","journal-title":"J Immunother Cancer"},{"key":"1413_CR29","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s13346-018-0504-x","volume":"8","author":"M Kabiri","year":"2018","unstructured":"Kabiri M, et al. A stimulus-responsive, in situ-forming, nanoparticle-laden hydrogel for ocular drug delivery. Drug Deliv Transl Res. 2018;8:484\u201395.","journal-title":"Drug Deliv Transl Res"},{"key":"1413_CR30","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.apsusc.2017.05.078","volume":"419","author":"X Wang","year":"2017","unstructured":"Wang X, Wang G, Zhang Y. Research on the biological activity and doxorubicin release behavior in vitro of mesoporous bioactive SiO 2 -CaO-P 2 O 5 glass nanospheres. Appl Surf Sci. 2017;419:531\u20139.","journal-title":"Appl Surf Sci"},{"key":"1413_CR31","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.cherd.2015.07.021","volume":"104","author":"P Patil","year":"2015","unstructured":"Patil P, Khairnar G, Naik J. Preparation and statistical optimization of Losartan Potassium loaded nanoparticles using Box Behnken factorial design: Microreactor precipitation. Chem Eng Res Des. 2015;104:98\u2013109.","journal-title":"Chem Eng Res Des"},{"key":"1413_CR32","volume":"8","author":"FC Kenechukwu","year":"2022","unstructured":"Kenechukwu FC, et al. Potential enhancement of metformin hydrochloride in solidified reverse micellar solution-based PEGylated lipid nanoparticles targeting therapeutic efficacy in diabetes treatment. Heliyon. 2022;8: e09099.","journal-title":"Heliyon"},{"key":"1413_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4061\/2011\/120925","volume":"2011","author":"D Cesselli","year":"2011","unstructured":"Cesselli D, et al. Role of tumor associated fibroblasts in human liver regeneration, cirrhosis, and cancer. Int J Hepatol. 2011;2011:1\u201315.","journal-title":"Int J Hepatol"},{"key":"1413_CR34","doi-asserted-by":"crossref","first-page":"5863","DOI":"10.4238\/2013.November.22.14","volume":"12","author":"LN Xu","year":"2013","unstructured":"Xu LN, et al. Tumor-associated fibroblast-conditioned medium promotes tumor cell proliferation and angiogenesis. Genet Mol Res. 2013;12:5863\u201371.","journal-title":"Genet Mol Res"},{"key":"1413_CR35","first-page":"2334","volume":"40","author":"X Zhuang","year":"2018","unstructured":"Zhuang X, et al. Conditioned medium mimicking the tumor microenvironment augments chemotherapeutic resistance via ataxia-telangiectasia mutated and nuclear factor-\u03baB pathways in gastric cancer cells. Oncol Rep. 2018;40:2334\u201342.","journal-title":"Oncol Rep"},{"key":"1413_CR36","doi-asserted-by":"crossref","first-page":"5693","DOI":"10.2147\/IJN.S314472","volume":"2021","author":"Y Ezzeldeen","year":"2021","unstructured":"Ezzeldeen Y, Swidan S, ElMeshad A, Sebak A. Green synthesized Honokiol Transfersomes relieve the immunosuppressive and stem-like cell characteristics of the aggressive B16F10 melanoma. Int J Nanomedicine. 2021;2021:5693\u2013712.","journal-title":"Int J Nanomedicine"},{"key":"1413_CR37","volume":"18","author":"A Ramzy","year":"2022","unstructured":"Ramzy A, et al. Drugless nanoparticles tune-up an array of intertwined pathways contributing to immune checkpoint signaling and metabolic reprogramming in triple-negative breast cancer. Biomed Mater. 2022;18: 015023.","journal-title":"Biomed Mater"},{"key":"1413_CR38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.yjmcc.2015.05.007","volume":"85","author":"SCW Stevens","year":"2015","unstructured":"Stevens SCW, et al. Losartan treatment attenuates tumor-induced myocardial dysfunction. J Mol Cell Cardiol. 2015;85:37\u201347.","journal-title":"J Mol Cell Cardiol"},{"key":"1413_CR39","doi-asserted-by":"crossref","unstructured":"Qi X,\u00a0et al. Metformin sensitizes the response of oral squamous cell carcinoma to cisplatin treatment through inhibition of NF-\u03baB\/HIF-1\u03b1 signal axis. Scientific Rep. 2016;6:1\u201312.","DOI":"10.1038\/srep35788"},{"key":"1413_CR40","unstructured":"Bernstein SE. Chapter 16 - Physiological characteristics. In: Green EL, editor. Biology of the laboratory mouse. New York, Blakiston Division, McGraw-Hill; 1966."},{"key":"1413_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2018.11.070","volume":"556","author":"K Yoncheva","year":"2019","unstructured":"Yoncheva K, et al. Optimization and in-vitro\/in-vivo evaluation of doxorubicin-loaded chitosan-alginate nanoparticles using a melanoma mouse model. Int J Pharm. 2019;556:1\u20138.","journal-title":"Int J Pharm"},{"key":"1413_CR42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0091808","volume":"9","author":"W Sievert","year":"2014","unstructured":"Sievert W, et al. Adhesion molecule expression and function of primary endothelial cells in benign and malignant tissues correlates with proliferation. PLoS ONE. 2014;9: e91808.","journal-title":"PLoS ONE"},{"key":"1413_CR43","volume":"72","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, et al. Effects of polysaccharides from bee collected pollen of Chinese wolfberry on immune response and gut microbiota composition in cyclophosphamide-treated mice. J Funct Foods. 2020;72: 104057.","journal-title":"J Funct Foods"},{"key":"1413_CR44","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ijpharm.2018.06.057","volume":"548","author":"M Rady","year":"2018","unstructured":"Rady M, Gomaa I, Afifi N, Abdel-Kader M. Dermal delivery of Fe-chlorophyllin via ultradeformable nanovesicles for photodynamic therapy in melanoma animal model. Int J Pharm. 2018;548:480\u201390.","journal-title":"Int J Pharm"},{"key":"1413_CR45","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s11010-022-04378-4","volume":"477","author":"M Abdel-Latif","year":"2022","unstructured":"Abdel-Latif M, et al. MALAT-1\/p53\/miR-155\/miR-146a ceRNA circuit tuned by methoxylated quercitin glycoside alters immunogenic and oncogenic profiles of breast cancer. Mol Cell Biochem. 2022;477:1281\u201393.","journal-title":"Mol Cell Biochem"},{"key":"1413_CR46","doi-asserted-by":"crossref","DOI":"10.14440\/jbm.2019.281","volume":"6","author":"PK Bommareddy","year":"2019","unstructured":"Bommareddy PK, Lowe DB, Kaufman HL, Rabkin SD, Saha D. Multi-parametric flow cytometry staining procedure for analyzing tumor-infiltrating immune cells following oncolytic herpes simplex virus immunotherapy in intracranial glioblastoma. J Biol Methods. 2019;6: e112.","journal-title":"J Biol Methods"},{"key":"1413_CR47","doi-asserted-by":"crossref","unstructured":"Orecchioni M, Ghosheh Y, Pramod AB, Ley K. Macrophage polarization: different gene signatures in M1(Lps+) vs. Classically and M2(LPS-) vs. Alternatively activated macrophages. Front Immunol. 2019;10:1084.","DOI":"10.3389\/fimmu.2019.01084"},{"key":"1413_CR48","first-page":"1","volume":"13","author":"Q Zhao","year":"2022","unstructured":"Zhao Q, et al. Enhanced therapeutic efficacy of combining Losartan and chemo-immunotherapy for triple negative breast cancer. Front Immunol. 2022;13:1\u201313.","journal-title":"Front Immunol"},{"key":"1413_CR49","unstructured":"Verma A, Ratnawat S, Gupta AK, Jain S. PLGA nanoparticles for delivery of Losartan potassium through intranasal route: development and characterization. Int J Drug Dev Res.\u00a02013;5."},{"key":"1413_CR50","doi-asserted-by":"crossref","first-page":"101042831879788","DOI":"10.1177\/1010428318797880","volume":"40","author":"K Sawa-Wejksza","year":"2018","unstructured":"Sawa-Wejksza K, Dudek A, Lemieszek M, Ka\u0142awaj K, Kandefer-Szersze\u0144 M. Colon cancer\u2013derived conditioned medium induces differentiation of THP-1 monocytes into a mixed population of M1\/M2 cells. Tumor Biol. 2018;40:101042831879788.","journal-title":"Tumor Biol"},{"key":"1413_CR51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0622-0","volume":"7","author":"B Benner","year":"2019","unstructured":"Benner B, et al. Generation of monocyte-derived tumor-associated macrophages using tumor-conditioned media provides a novel method to study tumor-associated macrophages in vitro. J Immunother Cancer. 2019;7:1\u201314.","journal-title":"J Immunother Cancer"},{"key":"1413_CR52","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1042\/BST20160387","volume":"45","author":"Erdogan B, Webb DJ","year":"2017","unstructured":"Erdogan B, Webb DJ. Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis. Biochem Soc Trans. 2017;45:229\u201336. https:\/\/doi.org\/10.1042\/BST20160387.","journal-title":"Biochem Soc Trans"},{"key":"1413_CR53","doi-asserted-by":"crossref","unstructured":"Nairon KG, DePalma TJ, Zent JM, Leight JL, Skardal A. Tumor cell-conditioned media drives collagen remodeling via fibroblast and pericyte activation in an in vitro premetastatic niche model. iScience.\u00a02022;25:104645.","DOI":"10.1016\/j.isci.2022.104645"},{"key":"1413_CR54","doi-asserted-by":"publisher","unstructured":"Watanabe S, Boucrot E. Fast and ultrafast endocytosis. Curr Opin Cell Biol. 2017;47:64\u201371.\u00a0https:\/\/doi.org\/10.1016\/j.ceb.2017.02.013.","DOI":"10.1016\/j.ceb.2017.02.013"},{"key":"1413_CR55","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1091\/mbc.E17-06-0419","volume":"29","author":"DS Redka","year":"2018","unstructured":"Redka DS, G\u00fctschow M, Grinstein S, Canton J. Differential ability of proinflammatory and anti-inflammatory macrophages to perform macropinocytosis. Mol Biol Cell. 2018;29:53\u201365.","journal-title":"Mol Biol Cell"},{"key":"1413_CR56","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1039\/c6ib00133E","volume":"9","author":"L Ma","year":"2017","unstructured":"Ma L, Bygd HC, Bratlie KM. Improving selective targeting to macrophage subpopulations through modifying liposomes with arginine based materials. Integr Biol (United Kingdom). 2017;9:58\u201367.","journal-title":"Integr Biol (United Kingdom)"},{"key":"1413_CR57","doi-asserted-by":"crossref","first-page":"36441","DOI":"10.18632\/oncotarget.5541","volume":"6","author":"L Ding","year":"2015","unstructured":"Ding L, et al. Metformin prevents cancer metastasis by inhibiting M2-like polarization of tumor associated macrophages. Oncotarget. 2015;6:36441\u201355.","journal-title":"Oncotarget"},{"key":"1413_CR58","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1111\/jcmm.13655","volume":"22","author":"JC Wang","year":"2018","unstructured":"Wang JC, et al. Metformin\u2019s antitumour and anti-angiogenic activities are mediated by skewing macrophage polarization. J Cell Mol Med. 2018;22:3825\u201336.","journal-title":"J Cell Mol Med"},{"key":"1413_CR59","doi-asserted-by":"crossref","first-page":"7656","DOI":"10.7150\/thno.44567","volume":"10","author":"Y Li","year":"2020","unstructured":"Li Y, et al. TGF-\u03b2 causes docetaxel resistance in prostate cancer via the induction of Bcl-2 by acetylated KLF5 and protein stabilization. Theranostics. 2020;10:7656\u201370.","journal-title":"Theranostics"},{"key":"1413_CR60","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa198","author":"E Nie","year":"2020","unstructured":"Nie E, et al. TGF-\u03b21 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT. Neuro Oncol. 2020. https:\/\/doi.org\/10.1093\/neuonc\/noaa198.","journal-title":"Neuro Oncol"},{"key":"1413_CR61","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.toxlet.2018.05.036","volume":"295","author":"S Saber","year":"2018","unstructured":"Saber S, et al. Perindopril, fosinopril and losartan inhibited the progression of diethylnitrosamine-induced hepatocellular carcinoma in mice via the inactivation of nuclear transcription factor kappa-B. Toxicol Lett. 2018;295:32\u201340.","journal-title":"Toxicol Lett"},{"key":"1413_CR62","doi-asserted-by":"crossref","unstructured":"Jung MY, Kang JH, Leof EB. Transforming growth factor beta induced PD-L1 expression promotes pro-fibrotic signaling. J Immunol.\u00a02020;204.","DOI":"10.4049\/jimmunol.204.Supp.79.8"},{"key":"1413_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/J.DRUDIS.2021.11.015","author":"Y Fu","year":"2021","unstructured":"Fu Y, Saraswat AL, Monpara J, Patel K. Stromal disruption facilitating invasion of a \u2018nano-arsenal\u2019 into the solid tumor. Drug Discov Today. 2021. https:\/\/doi.org\/10.1016\/J.DRUDIS.2021.11.015.","journal-title":"Drug Discov Today"},{"key":"1413_CR64","unstructured":"Naba NM, Tolay N, Erman B, Sayi Yazgan A. Doxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116 cells, opposite to its effects on MDA-MB-231 cells. Turk J Biol.\u00a02020;44:15\u201323."},{"key":"1413_CR65","doi-asserted-by":"crossref","unstructured":"Ghebeh H,\u00a0et al. Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule. Breast Cancer Res.\u00a02010;12.","DOI":"10.1186\/bcr2605"},{"key":"1413_CR66","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.biomaterials.2017.09.017","volume":"148","author":"W Song","year":"2017","unstructured":"Song W, Musetti SN, Huang L. Nanomaterials for cancer immunotherapy. Biomaterials. 2017;148:16\u201330.","journal-title":"Biomaterials"},{"key":"1413_CR67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13040678","volume":"13","author":"A Procureur","year":"2021","unstructured":"Procureur A, Simonaggio A, Bibault JE, Oudard S, Vano YA. Enhance the immune checkpoint inhibitors efficacy with radiotherapy induced immunogenic cell death: a comprehensive review and latest developments. Cancers (Basel). 2021;13:1\u201319.","journal-title":"Cancers (Basel)"},{"key":"1413_CR68","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1089\/ten.tea.2013.0473","volume":"20","author":"M Tiago","year":"2014","unstructured":"Tiago M, et al. Fibroblasts protect melanoma cells from the cytotoxic effects of doxorubicin. Tissue Eng Part A. 2014;20:2412.","journal-title":"Tissue Eng Part A"},{"key":"1413_CR69","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.18632\/oncotarget.6210","volume":"7","author":"TB Steinbichler","year":"2016","unstructured":"Steinbichler TB, Metzler V, Pritz C, Riechelmann H, Dudas J. Tumor-associated fibroblast-conditioned medium induces CDDP resistance in HNSCC cells. Oncotarget. 2016;7:2508\u201318.","journal-title":"Oncotarget"},{"key":"1413_CR70","first-page":"1","volume":"11","author":"Y Lu","year":"2021","unstructured":"Lu Y, et al. Metformin downregulates PD-L1 expression in esophageal squamous cell catrcinoma by inhibiting IL-6 signaling pathway. Front Oncol. 2021;11:1\u201312.","journal-title":"Front Oncol"},{"key":"1413_CR71","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1021\/jacs.0c00650","volume":"142","author":"H Han","year":"2020","unstructured":"Han H, et al. Metformin-induced stromal depletion to enhance the penetration of gemcitabine-loaded magnetic nanoparticles for pancreatic cancer targeted therapy. J Am Chem Soc. 2020;142:4944\u201354.","journal-title":"J Am Chem Soc"},{"key":"1413_CR72","doi-asserted-by":"crossref","unstructured":"Kim SI, Cassella CR, Byrne KT. Tumor burden and immunotherapy: impact on immune infiltration and therapeutic outcomes. Front Immunol.\u00a02021;11.","DOI":"10.3389\/fimmu.2020.629722"},{"key":"1413_CR73","doi-asserted-by":"crossref","unstructured":"Castoldi L,\u00a0et al. Cytotoxic activity and lymphocyte subtypes in mice selected for maximal and minimal inflammatory response after transplantation of B16F10 and S91 melanoma cells. Int J Inflam. 2022.","DOI":"10.1155\/2022\/3298542"},{"key":"1413_CR74","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/cup.12749","volume":"43","author":"Y Zou","year":"2016","unstructured":"Zou Y, Billings SD. Myxoid cutaneous tumors: a review. J Cutan Pathol. 2016;43:903\u201318.","journal-title":"J Cutan Pathol"},{"key":"1413_CR75","doi-asserted-by":"crossref","unstructured":"Kamran N,\u00a0et al. Melanoma induced immunosuppression is mediated by hematopoietic dysregulation. Oncoimmunology. 2017;7.","DOI":"10.1080\/2162402X.2017.1408750"},{"key":"1413_CR76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-8-108","volume":"8","author":"S De Boo","year":"2009","unstructured":"De Boo S, et al. INOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells. Mol Cancer. 2009;8:1\u201318.","journal-title":"Mol Cancer"},{"key":"1413_CR77","volume":"24","author":"JG Navashenaq","year":"2020","unstructured":"Navashenaq JG, Zamani P, Nikpoor AR, Tavakkol-Afshari J, Jaafari MR. Doxil chemotherapy plus liposomal P5 immunotherapy decreased myeloid-derived suppressor cells in murine model of breast cancer. Nanomedicine. 2020;24: 102150.","journal-title":"Nanomedicine"},{"key":"1413_CR78","doi-asserted-by":"crossref","first-page":"25808","DOI":"10.18632\/oncotarget.25380","volume":"9","author":"FV Pereira","year":"2018","unstructured":"Pereira FV, et al. Metformin exerts antitumor activity via induction of multiple death pathways in tumor cells and activation of a protective immune response. Oncotarget. 2018;9:25808.","journal-title":"Oncotarget"},{"key":"1413_CR79","doi-asserted-by":"crossref","unstructured":"Zhang T,\u00a0et al. Metformin inhibits the urea cycle and reduces putrescine generation in colorectal cancer cell lines. Molecules.\u00a02021;26.","DOI":"10.3390\/molecules26071990"},{"key":"1413_CR80","doi-asserted-by":"publisher","unstructured":"Chandler C, Liu T, Buckanovich R, Coffman LG. The double edge sword of fibrosis in cancer. Transl Res.\u00a02019;209:55\u201367.\u00a0https:\/\/doi.org\/10.1016\/j.trsl.2019.02.006.","DOI":"10.1016\/j.trsl.2019.02.006"},{"key":"1413_CR81","doi-asserted-by":"crossref","first-page":"18640","DOI":"10.18632\/oncotarget.15553","volume":"8","author":"R Coulson","year":"2017","unstructured":"Coulson R, et al. The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma. Oncotarget. 2017;8:18640\u201356.","journal-title":"Oncotarget"},{"key":"1413_CR82","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.bbrc.2019.03.190","volume":"513","author":"N Zhao","year":"2019","unstructured":"Zhao N, Leng Q, Woodle MC, Mixson AJ. Enhanced tumor uptake and activity of nanoplex-loaded doxorubicin. Biochem Biophys Res Commun. 2019;513:242.","journal-title":"Biochem Biophys Res Commun"},{"key":"1413_CR83","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejpb.2021.05.007","volume":"165","author":"C Yunna","year":"2021","unstructured":"Yunna C, Mengru H, Fengling W, Lei W, Weidong C. Emerging strategies against tumor-associated fibroblast for improved the penetration of nanoparticle into desmoplastic tumor. Eur J Pharm Biopharm. 2021;165:75\u201383.","journal-title":"Eur J Pharm Biopharm"},{"key":"1413_CR84","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1096\/fj.07-9150com","volume":"22","author":"M Magzoub","year":"2008","unstructured":"Magzoub M, Jin S, Verkman AS. Enhanced macromolecule diffusion deep in tumors after enzymatic digestion of extracellular matrix collagen and its associated proteoglycan decorin. FASEB J. 2008;22:276\u201384.","journal-title":"FASEB J"},{"key":"1413_CR85","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.trecan.2018.02.005","volume":"4","author":"T Stylianopoulos","year":"2018","unstructured":"Stylianopoulos T, Munn LL, Jain RK. Reengineering the physical microenvironment of tumors to improve drug delivery and efficacy: from mathematical modeling to bench to bedside. Trends cancer. 2018;4:292\u2013319.","journal-title":"Trends cancer"},{"key":"1413_CR86","doi-asserted-by":"crossref","unstructured":"Scodeller P. Hyaluronidase and other extracellular matrix degrading enzymes for cancer therapy: new uses and nano-formulations. J Carcinog Mutagen.\u00a02014;5.","DOI":"10.4172\/2157-2518.1000178"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-023-01413-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-023-01413-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-023-01413-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T10:31:34Z","timestamp":1704191494000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-023-01413-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,23]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1413"],"URL":"https:\/\/doi.org\/10.1007\/s13346-023-01413-9","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,23]]},"assertion":[{"value":"8 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal experimentation protocols followed ARRIVE guidelines and were approved by the Research Ethics Committee of the Faculty of Pharmacy and Biotechnology, GUC (Project ID: PTC-2021-02).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}